• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Transkaryotic Therapies

Transkaryotic Therapies

  1. ETFs and Mutual Funds: Why not both?

    Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...

©2017 Morningstar Advisor. All right reserved.